New Drug Formulations of Posaconazole: Brief Clinical Pharmacology Review
Posaconazole is a second generation triazole with a broad spectrum of activity, which first appeared on the market in 2005 in the form of a suspension for oral administration. Despite some progress made in the framework of clinical trials, the problems associated with both the features of the pharma...
Main Author: | Veselov A.V. |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy
2016-11-01
|
Series: | Клиническая микробиология и антимикробная химиотерапия |
Subjects: | |
Online Access: | https://cmac-journal.ru/publication/2016/4/cmac-2016-t18-n4-p249/cmac-2016-t18-n4-p249.pdf |
Similar Items
-
The tablet formulation of posaconazole: clinical pharmacology and the use in patients with hematologic malignancies
by: Veselov A.V.
Published: (2020-05-01) -
Posaconazole
by: Bhattacharya M, et al.
Published: (2010-01-01) -
Deciphering the Relationship Between the Trough Concentration of Posaconazole and Its Efficacy and Safety in Chinese Patients With Hematological Disorders
by: Meng-Meng Jia, et al.
Published: (2020-10-01) -
Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis
by: Leelawattanachai P, et al.
Published: (2019-04-01) -
Successful treatment of azole-resistant invasive aspergillosis in a bottlenose dolphin with high-dose posaconazole
by: Paulien E. Bunskoek, et al.
Published: (2017-06-01)